Literature DB >> 12907047

The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre.

Otavio Bejzman Piltcher1, Vanessa Niemiec Teixeira, Marcelo Wierzynski de Oliveira, Isabella Scattolin, Simão Levin Piltcher.   

Abstract

UNLABELLED: Cystic fibrosis (CF) is considered one of the most prevalent lethal genetic disorders. The life expectancy of those patients has been rising. Besides the well-known prevalence of chronic rhinosinusitis, neurosensory hearing loss (NSHL) due to the large use of ototoxic antibiotics may be another problem that should receive special attention in otolaryngology (ENT).
OBJECTIVES: Define retrospectively the prevalence of NSHL among patients with CF from the Hospital de Clínicas de Porto Alegre (HCPA) and based on this data discuss the need for a specific out patient ENT-CF clinic. MATERIAL AND
METHOD: Files from CF HCPA patients were reviewed for age at diagnosis, the current age, types of antibiotics used, number of treatments, percentage with audiologic evaluation and its respective results.
RESULTS: One hundred and seven files were reviewed. The mean age at diagnosis was 1.33 years old (SD 1.97, range 0-12). The mean age of the sample was 7.87 (SD 4.49, range 1-22). Audiologic evaluation was performed in 39.3% (42) of the patients. 28.56% (12) had some degree of NSHL, while 36.3% did not present acoustic reflex. From 667 treatments with antibiotics, 49.5% were with tobramycin, 43.4% with amycacin and 7% with gentamicin.
CONCLUSIONS: The prevalence of NSHL among CF patients supports the need for a specific ENT-CF outpatient clinic. This clinic would help on the prevention and treatment of NSHL due to the use of ototoxic antibiotics and on the better understanding/control of rhinosinusal disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907047     DOI: 10.1016/s0165-5876(03)00135-6

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  9 in total

1.  Changes in the inner ear structures in cystic fibrosis patients.

Authors:  Henrique F Pauna; Rafael C Monsanto; Natsuko Kurata; Michael M Paparella; Sebahattin Cureoglu
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2016-11-16       Impact factor: 1.675

2.  d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.

Authors:  Daniel J Fox; Morris D Cooper; Cristian A Speil; Melissa H Roberts; Susan C Yanik; Robert P Meech; Tim L Hargrove; Steven J Verhulst; Leonard P Rybak; Kathleen C M Campbell
Journal:  J Cyst Fibros       Date:  2015-07-10       Impact factor: 5.482

3.  The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.

Authors:  Angela C Garinis; Campbell P Cross; Priya Srikanth; Kelly Carroll; M Patrick Feeney; Douglas H Keefe; Lisa L Hunter; Daniel B Putterman; David M Cohen; Jeffrey A Gold; Peter S Steyger
Journal:  J Cyst Fibros       Date:  2017-02-24       Impact factor: 5.482

4.  Cystic Fibrosis: Brazilian ENT Experience.

Authors:  Tania Sih; Ricardo Godinho; Leticia Paiva Franco; Otávio Piltcher
Journal:  Int J Otolaryngol       Date:  2012-05-06

5.  Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

Authors:  Fevzi Solmaz; Ercan Gündoğdu; Davut Akduman; Mehmet Haksever; Oğuzhan Dikici; Fatih Ünal
Journal:  Toxicol Rep       Date:  2016-03-22

Review 6.  Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

Authors:  F A Diepstraten; A E Hoetink; M van Grotel; A D R Huitema; R J Stokroos; M M van den Heuvel-Eibrink; A J M Meijer
Journal:  JAC Antimicrob Resist       Date:  2021-12-14

7.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

Review 8.  Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.

Authors:  Debora T M Caumo; Lúcia B Geyer; Adriane R Teixeira; Sérgio S M Barreto
Journal:  Braz J Otorhinolaryngol       Date:  2016-11-09

9.  High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.

Authors:  Lucia Bencke Geyer; Sergio Saldanha Menna Barreto; Liese Loureiro Weigert; Adriane Ribeiro Teixeira
Journal:  Braz J Otorhinolaryngol       Date:  2015-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.